Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine

Author： Sasaki Takashi  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.2, 2012-04, pp. : 708-713

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues

By Brieau Bertrand   Dahan Laetitia   De Rycke Yann   Boussaha Tarek   Vasseur Philippe   Tougeron David   Lecomte Thierry   Coriat Romain   Bachet Jean-Baptiste   Claudez Pierre   Zaanan Aziz   Soibinet Pauline   Desrame Jérome   Thirot-Bidault Anne   Trouilloud Isabelle   Mary Florence   Marthey Lysiane   Taieb Julien   Cacheux Wulfran   Lièvre Astrid  

Cancer, Vol. 121, Iss. 18, 2015-09 ,pp. : 3290-3297

Blackwell Publishing

Access to resources Recommend Favorite

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

By Tsavaris Nicolas   Kosmas Christos   Skopelitis Helias   Gouveris Panagiotis   Kopteridis Petros   Loukeris Dioynissis   Sigala Frantzeska   Zorbala-Sypsa Alexandra   Felekouras Evangelos   Papalambros Efstathios  

Investigational New Drugs, Vol. 23, Iss. 4, 2005-08 ,pp. : 369-375

Springer Publishing Company

Access to resources Recommend Favorite

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

By Boér Katalin  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 681-687

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions

By Lin Nancy   Parker Leroy   Come Steven   Burstein Harold   Haldoupis Margaret   Ryabin Nicole   Gelman Rebecca   Winer Eric   Shulman Lawrence  

Investigational New Drugs, Vol. 25, Iss. 4, 2007-08 ,pp. : 369-375

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer

By El-Rayes Basil   Zalupski Mark   Shields Anthony   Ferris Ann   Vaishampayan Ulka   Heilbrun Lance   Venkatramanamoorthy Raghu   Adsay Volkan   Philip Philip  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 583-590

Springer Publishing Company

Access to resources Recommend Favorite